Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)

2.250 +0.390 (+20.97%) As of 11:59AM HKT. Market open.

Jacobio Pharmaceuticals Group Co., Ltd.

Building F2
No. 88 Kechuang 6th Street Beijing Economic-Technological Development Area
Beijing
China
86 10 5631 5466
https://www.jacobiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 301

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yinxiang Wang	Executive Chairman & CEO	3.18M	N/A	1965
Ms. Xiaojie Wang	Executive Director & President of Administration	2.42M	N/A	1965
Ms. Yunyan Hu	Executive VP & Executive Director	2.56M	N/A	1962
Ms. Tao Yang	Vice President of Human Resources	N/A	N/A	N/A
Dr. Andrea Wang-Gillam M.D., Ph.D.	Executive VP, Chief Medical Officer and Global Head of R&D	N/A	N/A	1971
Ms. Yanping Wang	Executive Vice President of Non-Clinical R&D	N/A	N/A	N/A
Dr. Haijun Wang	Senior Vice President of Information & Data Management	N/A	N/A	N/A
Dr. Wei Long	Head of Drug Discovery	N/A	N/A	N/A
Ms. Yuli Ding	Executive Vice President of Clinical Development	N/A	N/A	N/A
Ms. Qing Xue	Joint Company Secretary	N/A	N/A	1989

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Jacobio Pharmaceuticals Group Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-(L)1 resistant cancer; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. The company was founded in 2015 and is headquartered in Beijing, China.

Corporate governance

Jacobio Pharmaceuticals Group Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.